Shao‐Lan Qin
Impact in
-
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 10
- Cancer Immunotherapy and Biomarkers 4
- Colorectal Cancer Surgical Treatments 3
-
- Ubiquitin and proteasome pathways 3
- Co-authors
- Ming Zhong (20 shared papers)Yifei Mu (16 shared papers)Yang Luo (17 shared papers)Minhao Yu (15 shared papers)Qi Yang (3 shared papers)Zhengshi Wang (6 shared papers)Ran Cui (7 shared papers)Jun Qin (6 shared papers)
- Journals
- Biomedicine & Pharmacotherapy (3 papers)Biochemical and Biophysical Research Communications (1 paper)Medicine (1 paper)BMC Surgery (1 paper)OncoImmunology (1 paper)
- Partner nations
- ChinaNepalUnited States
In The Last Decade
Shao‐Lan Qin
26 papers receiving 495 citations
Peers
Comparison fields: 5 of 63
- Cancer Research 116
- Oncology 152
- Immunology 79
- Molecular Biology 234
- Cell Biology 38
Countries citing papers authored by Shao‐Lan Qin
This map shows the geographic impact of Shao‐Lan Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shao‐Lan Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shao‐Lan Qin more than expected).
Fields of papers citing papers by Shao‐Lan Qin
This network shows the impact of papers produced by Shao‐Lan Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shao‐Lan Qin. The network helps show where Shao‐Lan Qin may publish in the future.
Co-authors
The 25 scholars most cited alongside Shao‐Lan Qin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 72 | |
| 2 | 2019 | 35 | |
| 3 | Up-regulated CKS2 promotes tumor progression and predicts a poor prognosis in human colorectal cancer. | 2015 | 35 |
| 4 | 2016 | 34 | |
| 5 | 2016 | 31 | |
| 6 | 2015 | 30 | |
| 7 | miR-193b directly targets STMN1 and inhibits the malignant phenotype in colorectal cancer. | 2016 | 29 |
| 8 | 2017 | 28 | |
| 9 | 2020 | 27 | |
| 10 | 2018 | 23 | |
| 11 | Decreased expression of interleukin-36α predicts poor prognosis in colorectal cancer patients. | 2014 | 22 |
| 12 | 2015 | 17 | |
| 13 | 2019 | 16 | |
| 14 | 2018 | 13 | |
| 15 | Increased expression of Rab5A predicts metastasis and poor prognosis in colorectal cancer patients. | 2015 | 12 |
| 16 | 2022 | 11 | |
| 17 | 2016 | 11 | |
| 18 | 2015 | 11 | |
| 19 | 2019 | 10 | |
| 20 | 2021 | 9 |
About Shao‐Lan Qin
Shao‐Lan Qin is a scholar working on Oncology, Molecular Biology, Cancer Research, Pathology and Forensic Medicine and Cell Biology, having authored 26 papers that have together received 495 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), MicroRNA in disease regulation (4 papers), Ubiquitin and proteasome pathways (3 papers), Colorectal Cancer Surgical Treatments (3 papers), Genetic factors in colorectal cancer (3 papers), Cancer-related molecular mechanisms research (3 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Cancer Research (116 citations), Oncology (152 citations), Immunology (79 citations), Molecular Biology (234 citations) and Cell Biology (38 citations). Shao‐Lan Qin has collaborated with scholars based in China, Nepal and United States. Frequent co-authors include Ming Zhong, Yifei Mu, Yang Luo, Minhao Yu, Qi Yang, Zhengshi Wang, Ran Cui, Jun Qin, Guangyao Ye and Yan Zhang. Their work appears in journals such as Biomedicine & Pharmacotherapy, Biochemical and Biophysical Research Communications, Medicine, BMC Surgery and OncoImmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.